Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs
-
- Sangeun Jeon
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea
-
- Meehyun Ko
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea
-
- Jihye Lee
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea
-
- Inhee Choi
- Medicinal Chemistry, Institut Pasteur Korea, Seongnam, South Korea
-
- Soo Young Byun
- Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea
-
- Soonju Park
- Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea
-
- David Shum
- Screening Discovery Platform, Institut Pasteur Korea, Seongnam, South Korea
-
- Seungtaek Kim
- Zoonotic Virus Laboratory, Institut Pasteur Korea, Seongnam, South Korea
抄録
<jats:p> Drug repositioning is the only feasible option to immediately address the COVID-19 global challenge. We screened a panel of 48 FDA-approved drugs against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were preselected by an assay of SARS-CoV. We identified 24 potential antiviral drug candidates against SARS-CoV-2 infection. Some drug candidates showed very low 50% inhibitory concentrations (IC <jats:sub>50</jats:sub> s), and in particular, two FDA-approved drugs—niclosamide and ciclesonide—were notable in some respects. </jats:p>
収録刊行物
-
- Antimicrobial Agents and Chemotherapy
-
Antimicrobial Agents and Chemotherapy 64 (7), e00819-, 2020-06-23
American Society for Microbiology